A number of firms have modified their ratings and price targets on shares of Cidara Therapeutics (NASDAQ: CDTX) recently:

  • 8/14/2017 – Cidara Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “
  • 8/11/2017 – Cidara Therapeutics was upgraded by analysts at WBB Securities from a “sell” rating to a “hold” rating.
  • 8/11/2017 – Cidara Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 8/10/2017 – Cidara Therapeutics was given a new $15.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/14/2017 – Cidara Therapeutics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 7/12/2017 – Cidara Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “
  • 7/11/2017 – Cidara Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $8.00 price target on the stock. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “
  • 6/26/2017 – Cidara Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $7.00 price target on the stock.
  • 6/24/2017 – Cidara Therapeutics was given a new $15.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 6/20/2017 – Cidara Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “
  • 6/19/2017 – Cidara Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “

Cidara Therapeutics, Inc. (NASDAQ CDTX) opened at 6.475 on Friday. The firm’s market capitalization is $109.19 million. Cidara Therapeutics, Inc. has a 1-year low of $5.60 and a 1-year high of $12.95. The stock has a 50 day moving average of $7.15 and a 200-day moving average of $7.41.

Cidara Therapeutics (NASDAQ:CDTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.91) by $0.08. On average, equities research analysts anticipate that Cidara Therapeutics, Inc. will post ($3.62) earnings per share for the current year.

In other Cidara Therapeutics news, CEO Jeffrey Stein purchased 15,000 shares of the business’s stock in a transaction on Monday, June 5th. The shares were purchased at an average cost of $5.95 per share, with a total value of $89,250.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Taylor Sandison purchased 20,000 shares of the business’s stock in a transaction on Wednesday, June 7th. The shares were acquired at an average cost of $5.90 per share, for a total transaction of $118,000.00. The disclosure for this purchase can be found here. Insiders own 18.90% of the company’s stock.

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Receive News & Ratings for Cidara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.